Firecrawl Alexandria

FDA

Name: FDA
Creator: FDA

US FDA drug, food and device enforcement recalls, Drugs@FDA applications and approval documents (letters, labels, reviews), complete response letters, orphan drug designations and approvals with exclusivity dates, Orange Book products with therapeutic equivalence codes, patents and exclusivities, the Purple Book of licensed biologics with reference product exclusivity and biosimilar and interchangeable status, the Paragraph IV patent certifications list, novel drug and first generic approvals, approved cell and gene therapies, structured labeling, device 510(k) decisions, PMA approvals and supplements, device classifications, GUDID device identifiers, MAUDE device and FAERS drug adverse-event reports, the UNII substance registry, the NDC directory, drug shortages, and warning letters, via openFDA, fda.gov, accessdata.fda.gov and the Purple Book.

16 Firecrawl tools use FDA

Try in Agent

Which interchangeable biosimilars reference Eylea, and when did each become interchangeable?

Try FDA now.

Choose an example or ask your own question.

What do you want to do with FDA?

FDA

TRY ASKING

Codefollows the fields above

const result = await firecrawl.scrape({
  alexandria: {
    provider: "fda-gov",
    capability: "records/drug_shortages",
    options: {
      limit: 1,
    },
  },
});

2Response example

This is a sample shape. Press Run to see live data from FDA.

dataset: drug_shortages
disclaimer: Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
last_updated: 2026-09-26
next_skip: 1
observed_at_ms: 1790553970698
pagination_truncated: false
skip: 0
source_url: https://api.fda.gov/drug/shortages.json?skip=0&limit=1
total_matching: 1601

data	record_id	source_url
	0009-0225-02	api.fda.gov/drug/shortages.json?search=package_ndc%3A%220009-0225-02%22&skip=0&limit=1

Source: U.S. Food and Drug Administration (FDA): openFDA (including MAUDE device adverse events, PMA, device classification, GUDID without GMDN content, and the UNII substance registry), the Orange Book and Purple Book data files, the Paragraph IV certification list, the novel drug, first generic and cellular and gene therapy approval lists, the orphan drug designation database, and warning letters. Public domain U.S. Government data; use does not imply FDA endorsement. (https://www.fda.gov/about-fda/about-website/website-policies)

Firecrawl tools

Ready-made Firecrawl tools that call FDA.

+1Produce recall traceback exposureUse when a grower, packer or fresh-produce buyer hears of a foodborne outbreak or recall in a crop they handle. Pulls the matching FDA recall records, reads published outbreak investigations for the pathogen and produce, checks which retail products list the ingredient, and returns an exposure note with what to check in your own lots.6 toolsOpen

Adverse event signal triage for a marketed drugUse when a pharmacovigilance scientist, medical affairs lead or hospital pharmacist sees a possible new safety signal for a marketed drug. Counts FAERS reports for the drug and reaction, checks whether the label already lists it, looks for published case reports and dedicated safety trials, and checks the EU regulatory picture, then rates the signal.6 toolsOpen

Connected medical device security intakeUse when a clinical engineering or medical device cybersecurity manager reviews a networked device before it goes on the hospital network. Reads the FDA clearance and any recalls, pulls the FCC radio grant and test exhibits for its wireless module, and searches for CVEs against the maker's products, producing an intake risk note for the biomed and IT security teams.7 toolsOpen

Drug recall pharmacy substitution planUse when a hospital pharmacy buyer or pharmacy operations manager learns of a drug recall. Identifies the recalled lots and every affected NDC, checks whether therapeutic alternatives are themselves in shortage in the US and EU, reads the alternative's label for dosing differences, and drafts a substitution and communication plan for nursing and prescribers.5 toolsOpen

Drug shortage impact assessmentUse when a hospital pharmacy director or supply chain lead learns a drug is short and needs to plan. Reads the FDA shortage entry, finds alternative labelers and presentations, checks recalls at the affected manufacturer, compares the EU shortage picture and lists clinical trials that depend on the drug.6 toolsOpen

Formulary addition evidence packUse when a P&T committee pharmacist or drug information specialist prepares a formulary review for a newly approved drug. Pulls the approval history and label, the pivotal and ongoing trials with results, published evidence from PubMed and early real-world adverse event reports, then drafts a sourced monograph with a recommendation.7 toolsOpen

Generic drug supply opportunity scanUse when a generics manufacturer, CDMO or pharma business-development lead is looking for molecules worth entering because supply is fragile. Lines up US and EU shortages for the same ingredient, counts how many labelers and approved applications remain, checks recent quality recalls, and ranks the molecules with the fewest reliable makers.6 toolsOpen

Medical device recall and 510(k) lineage checkUse when a hospital value-analysis committee, biomedical engineering lead or device buyer is evaluating a device before purchase or after a safety notice. Reads the 510(k) clearance and predicate, the manufacturer's recall record, product-liability dockets and, for public makers, risk disclosures, and returns approve, approve with monitoring or defer.5 toolsOpen

Post-marketing safety signal triageUse when a pharmacovigilance lead, medical affairs team or health journalist sees a possible new side effect for a marketed drug. Compares FAERS reaction reports against the current label, checks for published case reports, the EU regulatory status and ongoing trials, and returns a signal triage table with what is labelled, what is new and how strong the evidence is.6 toolsOpen

Benchmarks

Life sciences benchmarks

Quality, speed and cost, last 24 hours, across every agent call to FDA through Alexandria.

Quality: 97.6%; Calls answered without a tool error
Speed: 5.6 s; 95% of successful calls finish faster
Cost: 5 credits; Firecrawl credits per call
Calls: 450; Last 24 hours, every Alexandria user

Quality and speed of each tool, last 24 hours
Tool	Quality	Speed	Calls
Device udi	98.6%	833 ms	70
Orange book	97.1%	45.5 s	68
Warning letters	96.8%	3.9 s	62
Device clearances	100%	921 ms	58
Device recalls	96.1%	717 ms	51
Purple book	100%	792 ms	31
Drug recalls	92.9%	1.6 s	28
Paragraph iv certifications	100%	5.6 s	25

Browse the library

Get started

Give your agent FDA.

One API key for the live web and every provider in Alexandria.

Use FDA Explore Alexandria

Are you an AI agent? See setup options

FDA

Try FDA now.

Firecrawl tools

Benchmarks

Related providers